ONCIN Oncoinvent ASA
80.80NOK-2.42%Mkt Cap: 46.29M $P/E: —1d ago
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body…
Industry Peers
Biotechnology$127.54BUSDP/E 29.3
$81.13BUSD
$74.79BUSDP/E 18.0
$57.11BUSDP/E 34.8
$55.24BUSDP/E 36.1
$44.51BUSD
$41.63BUSDP/E 17.7
$41.14BUSDP/E 64.7
$32.74BUSDP/E 30.1
$29.42BUSDP/E 37.1
$25.84BUSD
$24.53BUSD
$24.01BUSDP/E 30.3
$23.13BUSDP/E 14.5
$22.67BUSD
$21.61BUSDP/E 29.3
$15.32BUSDP/E 16.2
$15.01BUSDP/E 17.5
$14.58BUSDP/E 18.6
$13.78BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
Oncoinvent ASA (STU:7BG) (Q2 2026) Earnings Call Highlights: Ovarian Cancer Trial Hits Halfway ... Oncoinvent ASA (STU:7BG) advances lead candidate Radspherin with strong recruitment and FDA fast track designation, while preparing for a larger phase 3 trial. | ||
Ookonomi24 | ||